Status:
TERMINATED
Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)
Lead Sponsor:
Inova Health Care Services
Collaborating Sponsors:
Brown University
Tufts University
Conditions:
Pulmonary Arterial Hypertension
Obstructive Sleep Apnea
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine whether pulmonary arterial hypertension can worsen or even cause sleep apnea. It is hypothesized that if pulmonary arterial hypertension does indeed worsen or...
Detailed Description
Pulmonary Arterial Hypertension (PAH) is associated with fluid retention. Currently, the treatment paradigm for newly diagnosed PAH patients includes evaluation for Obstructive Sleep Apnea (OSA). The ...
Eligibility Criteria
Inclusion
- • Diagnosis of Group 1 PAH
- Either lack of treatment for PAH or sub-optimally treated PAH as defined by NYHA FC 3 or 4
- Age 18 or older
- Ability to give consent
- Ability to undergo overnight polysomnogram
- Previously diagnosed OSA not on therapy
Exclusion
- Age younger than 18
- Pregnancy
- Previously diagnosed OSA and receiving therapy
- Inability to undergo overnight polysomnography in laboratory
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01835080
Start Date
April 1 2013
End Date
March 1 2014
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inova Heart and Vascular Institute/Inova Fairfax Hospital
Falls Church, Virginia, United States, 22042